Immune modulation and adjunctive immunotherapy — compounds assessed
The 5 compounds the Institute assesses in immune modulation and adjunctive immunotherapy.
§4Compounds assessed
Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.
-
Meta-analyses of hepatitis B trials report higher sustained virological response with thymosin alpha-1 as monotherapy or adjunct; a large Chinese randomised trial in sepsis reported a mortality difference that a subsequent larger trial did not confirm — Rated…
Moderate -
No assessable evidence identified — —
Very low -
No assessable randomised evidence for immune outcomes — —
Very low -
No randomised human evidence for systemic immune effects — —
Very low -
Russian clinical reports describe immunological and clinical effects across a wide range of conditions — For a substance of undefined composition, the Institute cannot in principle assign a certainty rating above very low, because the intervention itself is…
Very low
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Garaci E, Pica F, Serafino A, Balestrieri E, Matteucci C, Moroni G, Sorrentino R, Zonfrillo M, Pierimarchi P, Sinibaldi-Vallebona P. Thymosin α1 and cancer: action on immune effector and tumor target cells. Annals of the New York Academy of Sciences 2007;1112:225–234. doi:10.1196/annals.1415.025 · PMID 17567944
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.